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A B S T R A C T
Previous studies have recommended that probiotics may have blood pressure (BP)-lowering effects. However,
they examined all probiotic strains (multi/single probiotics) simultaneously. In respect to strain specificity
properties of probiotic, the aim of the present study was to systematically investigate the role of Lactobacillus
plantarum as an anti-hypertensive agent by performing a meta-analysis of randomized controlled trials. PubMed,
Scopus, Cochrane Library and Google Scholar were used from inception until October 2018 to identify eligible
trials. We used random-effects model as the preferable method to assess the combined treatment effect. We
further conducted sensitivity analysis and stratified analysis. Seven studies with 653 participants were included
in the meta-analysis. The pooled weighted mean difference (WMD) with the random effects model showed a
significant effects of Lactobacillus plantarum supplementation on improvement of SBP with no statistically sig-
nificant heterogeneity (WMD: -1.58 mmHg, 95 % CI: -3.05 to 0.11) (heterogeneity P = 0.14; I² = 36 %). The
overall effect in the DBP showed significant pooled estimates (WMD: -0.92 mmHg, 95 % CI: -1.49 to -0.35) with
a complete homogeneity between the studies (heterogeneity P = 0.46; I² = 0 %). The findings of the present
meta-analysis study support the use of Lactobacillus plantarum supplementation for lowering systolic and dia-
stolic blood pressure. The clinical significance of blood pressure-lowering effect of Lactobacillus Plantarum
supplementation is not considerable; however, given the overarching benefits evident and concurrent lack of
specific side effects, further trials are warranted to clarify the effects of Lactobacillus Plantarum probiotics par-
ticularly for hypertensive patients.
1. Introduction
Hypertension (HTN) is one of the major risk factors of cardiovas-
cular disease worldwide [1–3], with an extensive prevalence reaching
over one billion people all over the world [4]. In recent years, the use of
nutritional therapy in the management of HTN has been given much
attention [5]. Several nutraceuticals have shown to enhance the effi-
cacy of classic pharmacological treatments. An improvement in the
quality of the treatment such as adherence to therapy and achieving
clinically optimal blood pressure is associated with the use of blood
pressure-lowering nutraceuticals [6]. Therapeutic diets such as DASH
(Dietary Approaches to Stop Hypertension) along with the use of nu-
merous herbal compounds (e.g., turmeric, cinnamon, and ginger) have
shown positive and significant impacts on HTN as well as inflammatory
conditions in humans [7,8].
One of the highlighted therapeutic approaches is probiotic
supplements that have emerged as a new therapeutic option in the
treatment of cardiovascular diseases. Recently, several studies have
suggested that the use of probiotics is associated with significant effects
on a wide range of diseases including HTN, atherosclerosis, in-
flammatory and cardiovascular diseases [9]. Lactobacillus plantarum is
one of the most important probiotics that is employed as a nutritional
supplement. It has been observed that this genus has some effects on
metabolic disorders and cardiovascular diseases [10,11]. A number of
clinical trials have been conducted to evaluate the effect of Lactobacillus
plantarum on HTN [12]. However, the results of these studies were
inconsistent; In the Hariri's study, supplementation with Lactobacillus
plantarum showed a significant reduction in HTN, while in another
study by Sharafedtinov, the use of Lactobacillus plantarum had no sig-
nificant effect on blood pressure subjects compared to the placebo
group [12,13]. Several meta-analyses have also been published in-
vestigating the role of probiotics in hypertensive patients. These studies
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revealed the positive effects of probiotic supplementation on lowering
blood pressure [14–17]. Given that the effects of each probiotic are
specific (Strain-Specificity), and a particular strain may show different
effects on blood pressure, it is recommended to examine each strain
separately. There has not been a comprehensive meta-analytical study
on the effect of Lactobacillus plantarum supplementation on blood
pressure; thus, we conducted a systematic review and meta-analysis of
randomized clinical trials (RCTs) on the role of Lactobacillus plantarum
including all sub-strains as an anti-hypertensive, as to our knowledge,
this topic has not been assessed previously.
2. Materials and methods
We conducted our systematic review and meta-analysis based on the
recommendations and guidelines reported in PRISMA (Preferred
Reporting Items for Systematic reviews and Meta-Analysis) [18,19].
2.1. Literature search
Two independent researchers searched several databases including
PubMed, Scopus, Cochrane Library and Google Scholar from inception
until October 2018. Terms used for the search included [Lactobacillus
plantarum OR L. plantarum AND hypertension OR high blood pressure
OR SBP OR DBP] in an attempt to find all related clinical trials in-
vestigating the effects of Lactobacillus plantarum on high blood pressure.
We also hand searched the reference lists of eligible studies. Any dis-
agreement between the two researchers was discussed and resolved by
a third researcher.
2.2. Study selection
Studies were considered for inclusion in our systematic review if
they fulfill the following inclusion criteria [1] examined the effects of
Lactobacillus plantarum on blood pressure as the primary or secondary
outcome [2], Lactobacillus plantarum (including all sub-strains) was
administered as either single strain or multi-strain supplement [3],
randomized, placebo-controlled trials [4], reported either the mean (or
net change of) systolic and/or diastolic blood pressure and associated
standard deviation (SD) or the necessary values for calculating the
parameters. We excluded cohort or cross-sectional studies, reports that
did not include control group or placebo, as well as animal studies. All
studies were screened independently by two researchers and any con-
flict discussed by the third researcher to determine the final outcome.
Fig. 1 shows the process of inclusion of studies in the systematic review.
2.3. Data extraction
Two sections of data were extracted from the included articles: basic
and main characteristics. Basic characteristics comprised name of the
author, year of publication, country where the trial was conducted,
design of the study (parallel, cross-over, etc.), age and sex of the sub-
jects, duration of the study, supplementation dosage, clinical condition
and initial systolic and diastolic blood pressure measurements of the
intervention group. With respect to the main characteristics, mean
systolic and diastolic blood pressure (SBP/DBP) in intervention and
control groups with their standard deviations (SD) and the number of
subjects in the intervention and placebo groups were extracted from the
main text, tables, figures or supplementary data. In the case of missing
data, we contacted corresponding authors for missing data.
2.4. Quality assessment
A systematic assessment of bias was conducted using Jadad scale
[20]. We evaluated the included RCTs for [1] statement of randomi-
zation and method of random allocation [2]; use of blinding and
method applied [3]; detail of withdrawals/dropouts. Both of the
randomization and blinding sections have a maximum of 2 points, and
the dropouts section can earn 1 point. The minimum score which can be
earned for each article is 0 and its maximum is 5. Articles with score
of< 3 were considered as low-quality articles and those with a score of
≥ 3 were considered as high-quality ones [20].
2.5. Statistical analysis
For the statistical analyses, we used Review Manager Software
(RevMan 5.3; Cochrane Collaboration, Oxford, England) and
Comprehensive Meta-Analysis (version 3.2; Biostat). In order to assess
the effects of Lactobacillus plantarum on blood pressure, we used the
weighted mean difference (WMD) and its 95 % confidence interval.
Following Cochrane, we used mean and SD values for blood pressure
(SBP/DBP) before and after using the supplements in both intervention
and placebo groups to calculate the effect size [21]. According to Hozo
et al., all studies' median values and their ranges or their confidence
intervals (CI) were converted to mean and SD [22]. Heterogeneity be-
tween studies was evaluated by the Cochran’s Q-test at P< 0.05 level of
significance and I2 test. A random-effects model was employed in the
meta-analysis. We carried out subgroups analysis to investigate poten-
tial sources of heterogeneity which we expected to include: duration of
study (≤ 7 weeks and>7 weeks), blood pressure in subjects (normal,
elevated and hypertension) and the content of supplements used in
intervention (Lactobacillus plantarum supplements or multi-strain sup-
plements that contained Lactobacillus plantarum). We also carried out
sensitivity analyses to assess the effect of each trial on the pooled es-
timate. We applied Begg's funnel plot to determine publication bias
[23]. Begg's rank correlation test and Egger's regression test were used
to infix funnel plot incommensurability [24].
3. Results
3.1. Search results and study eligibility
Fig. 1 shows the process of study selection. A total of 1642 papers
were retrieved primarily from the electronic searches. Two of the au-
thors reviewed the title and abstracts of the papers at a later step and
duplicates and studies that were not related to Lactobacillus plantarum
and blood pressure were removed. In the next step, the full texts of the
remaining articles were read. Two studies were excluded due to lack of
a placebo group, 3 studies were not written in English, one study was
also excluded due to lack of appropriate study design and another for
the low-quality score based on the Jadad scale. Finally, seven studies
were included in our systematic review and meta-analysis.
3.2. Description of the studies
The included clinical trials were published between 2002 and 2017
in South Korea [25], Iran [13], Estonia [26], the United States [27],
Poland [28], Russia [12] and Sweden [29]. Four studies were double-
blinded, randomized, placebo-controlled trials [13,25,27,28] and three
were designed as a parallel study [12,26,29]. In the study of Shar-
afedtinov et al., systolic and diastolic blood pressure were measured in
the morning and evening, but for the analysis, we used only the blood
pressure of the morning [12]. Two interventions have been carried out
in the Xu et al. study, which was designed as a parallel design; but given
that results might have been affected by the potential antihypertensive
effect of the intake of blueberries, which are fermented by Lactobacillus
plantarum, we did not analyze this intervention [29]. A total of 653
subjects were analyzed in this study, 337 subjects were in the inter-
vention group and 316 subjects were in the placebo group. All of the
participants in the studies were both males and females who had dif-
ferent clinical conditions including hypertension [29], hypertriglycer-
idemia [25], obesity [12], type 2 diabetes mellitus [13] and smoking
[28]. The duration of trials varied from 2 to 12 weeks. Baseline systolic
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blood pressure (SBP) ranged from 115.08 mmHg to 151.5 mmHg in the
intervention group. The baseline diastolic blood pressure (DBP) in the
intervention group ranged from 68.44 mmHg to 100 mmHg. All in-
cluded trials reported both systolic and diastolic blood pressures before
and after the intervention [12,13,25–29]. The lowest daily dose of
Lactobacillus plantarum was 109 cfu of Lactobacillus plantarum DSM
15313 which was administered in Xu study [29] and the highest dose
was used in Sharafedtinov's study with 1.5 × 1012 cfu/day of Lacto-
bacillus plantarum TENSIA [12]. Regarding the intervention groups, two
studies used probiotic dairy products [12,26], 3 trials used probiotic
drinks [13,28,29] and one study used probiotic capsules as supple-
mentation in the intervention group [27]. The treatments in control
groups of included studies were: Multi-component powder [25], soy
milk [13] capsule filled with 0.6 g of cornstarch [27], Multi-component
structure including rosehip powder [28], probiotic-free cheese [12],
and probiotic-free placebo drink [29]. Five studies used Lactobacillus
plantarum as the probiotic supplementation [12,13,26,28,29] and 2
studies have used multi-strain probiotics supplement in addition to
Lactobacillus plantarum as the intervention [25,27]. There were no
serious reported side effects of Lactobacillus plantarum on individuals in
all of the included RCTs [12,13,25–29]. Table 1 shows the character-
istics of the included clinical trials.
3.3. Jadad score assessment
Based on the assessment conducted by two independent researchers,
all the articles included in our systematic review were high quality
according to the Jadad scale. Table 2 shows the details of the Jadad
scoring of the clinical trials. The trials of Ahn, Sharafedtinov and Xu
received only one point of the blinding score as they have just men-
tioned that blinding was carried out [12,25,29]; however, the rest of
the studies received the highest score regarding this section [13,26–28].
Regarding randomization, only one study took one point for not re-
ferring to the random allocation method [26,28]. The remaining studies
were fully scored based on randomization [12,13,25,27,29]. All papers
scored one point due to stating the dropouts and participant with-
drawals [12,13,25,27,29], except for Hütt and Naruszewicz which did
not mention the fate of participants [26,28]. Finally, with respect to the
overall score that reflects the quality of the articles included, all papers
received a score of ≥ 3, which indicates that all included trials are of
high quality [12,13,25–29].
3.4. Pooled effect size of Lactobacillus plantarum supplementation on blood
pressure
The pooled weighted mean difference (WMD) with the random ef-
fects model showed a significant effects on improvement of SBP with a
non-significant heterogeneity after supplementation with Lactobacillus
plantarum (WMD: -1.58 mmHg, 95 % CI: -3.05 to -0.11, P< 0.05) (test
for heterogeneity P = 0.14; I² = 36 %). In respect to DBP, the overall
effect in the DBP showed significant pooled estimates (WMD: -0.92
mmHg, 95 % CI: -1.49 to -0.35) and there was complete homogeneity
between the studies (test for heterogeneity P = 0.46; I² = 0 %) (Fig. 2).
3.5. Subgroup analysis
Subgroup analysis was performed to identify potential sources of
heterogeneity and was based on a number of variables including: the
Fig. 1. Flow diagram of study selection.
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study duration, baseline blood pressure, and the composition of sup-
plements given (Table 3). Our findings indicated that SBP and DBP are
not associated with significant changes after subgroup analysis based
on the duration of supplementation. In other subgroup analysis based
on baseline blood pressure of subjects, individuals with hypertension
revealed a significant reduction in diastolic blood pressure with a non-
significant heterogeneity after supplementation with Lactobacillus
plantarum (WMD; -1.11 mmHg and its CI; -1.94 to -0.27). In the third
subgroup analysis which was based on the supplements components,
single strain supplements of Lactobacillus plantarum showed a sig-
nificant reduction on both SBP (WMD; -1.81 and its CI; -3.59 to -0.02, P
= 0.05, I2 = 50 %) and DBP level (WMD; -1.02 and its CI; -1.64 to
-0.41, P = 0.001, I2 = 0.0 %), while the meta-analysis of the multi-
strain supplements did not show any significant improvement of DBP in
favor of probiotic supplementation.
3.6. Sensitivity analysis
We executed a leave-one-out sensitivity analysis to explore the ef-
fect of single studies on the overall effect size. The pooled estimate of
mean difference of SBP and DBP ranged from -1.31 (95 % CI=-2.24,
-0.38) to -2.06 (95 % CI=-4.15, 0.02) in SBP and -0.53 (95 % CI=-1.20,
0.13) to -1.51 (95 % CI=-2.39, -0.63) in DBP (Fig. 3).
Table 2
Quality of the included studies based on the Jadad score.
Study; Year Blinding Randomization Withdrawals and
dropouts descriptions
Score
Ahn; 2015 1 2 1 4
Hariri; 2014 2 2 1 5
Hütt; 2015 2 1 0 3
Möller; 2017 2 2 1 5
Naruszewicz; 2002 2 1 0 3
Sharafedtinov;
2013
2 2 1 5
Xu; 2015 1 2 1 4
Fig. 2. Meta-analysis of the effects of Lactobacillus plantarum on A) SBP and B) DBP. Weight of studies was assigned by Review manager (Version 5.03) using the
sample size and SD. Sizes of data markers reveal the weight of each trial. The diamond represents the overall pooled effect size. Random effects model was used to
pool the standard mean differences of indicators. CI, confidence interval; I-squared inconsistency. SBP, systolic blood pressure; DBP, diastolic blood pressure.
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3.7. Publication bias assessment
No publication bias was identified according to the visual inspection
of funnel plots symmetry. Although, The Begg’s rank correlation test of
SBP revealed a slight publication bias (Kendall’s Tau with continuity
correction: -0.60; z = 2.10; two-tailed p = 0.03), other supplemental
methods including Begg’s rank correlation test of DBP (Kendall’s Tau
with continuity correction:-0.32; z = 1.11; two-tailed p = 0.26),
Egger’s linear regression test of SBP (intercept: -0.94; standard error:
0.60; 95 % CI: -2.41, 0.52; t = 1.57, df = 6; two-tailed p = 0.16); DBP:
(intercept:-0.24; standard error: 0.55; 95 % CI: -1.61, 1.11; t = 0.44, df
= 6; two-tailed p = 0.67)] verified the lack of publication bias for the
comparison of SBP and DBP levels between probiotic supplemented
groups and placebo groups (Fig. 4).
4. Discussion
To our knowledge, this systematic review is the first to summarize
the effect of Lactobacillus Plantarum probiotic supplementation on blood
pressure. Based on our analysis of seven randomized clinical trials that
assessed the role of this specific strain of probiotics on blood pressure,
we have found a modest, yet significant decrease in SBP and DBP when
pooling the results of included studies. Our results are to some extent
similar to those reported by a previous meta-analysis that assessed the
role of probiotics on blood pressure. However, some differences in our
results need to be addressed. Primarily, the magnitude of the change in
the BP was quite modest (reduction of SBP by 1.58 mmHg and DBP by
0.92 mmHg), even smaller than those reported by Khalesi et al. [15].
On the other hand, on conducting the subgroup analysis, we have found
that single-supplementation with Lactobacillus Plantarum intake has a
more pronounced effect on both systolic and diastolic BP in compared
with multi-strain probiotics. Furthermore, this significant effect was
only confined to those who had hypertension, not normotensives or
patients with elevated blood pressure.
The difference in findings might be attributed to the confining our
meta-analysis to one specific strain of probiotics which is Lactobacillus
Plantarum. Worth highlighting are the results of the subgroup analysis,
which showed that Lactobacillus Plantarum supplements intake exerted
a significant reduction on both SBP and DBP levels, while the use of the
multi-strain supplements did not show any significant reduction of
blood pressure. Though we must stress that the numbers of the
available randomized controlled studies addressing this topic are rela-
tively small and the effect observed is not substantial, yet, it might draw
the attention to this specific probiotic strain and a potential role in
lowering blood pressure. If this finding is proved in further studies,
Lactobacillus Plantarum might be a promising cheap adjuvant to anti-
hypertensive medications. This should be further investigated in clin-
ical trials as it is quite evident that the available literature lacks studies
that measure the potential effect of probiotics if administered in con-
junction with antihypertensive medications.
The mechanism of the potential antihypertensive effect of probiotics
and its protective effect on endothelial function has not been fully
understood but some recent studies have shown that high blood pres-
sure might be associated with gut microbiota dysbiosis, which suggests
that dietary interventions that correct gut microbiota, including pro-
biotics, could be applied as a new therapeutic strategy for hypertension
[30–32]. In a recent review by Robles-Vera et al. it has been demon-
strated that gut microbiota can potentially influence host BP through
multiple mechanisms including bacterial products that enter the cir-
culation [30]. They have also reported that specific strains of probio-
tics, including Lactobacillus, can synthesize neurotransmitters, and that
gut microbiota has important influences on host cell physiology
through bacterial metabolic products such as short-chain fatty acids or
trimethylamine-N-oxide or bacterial wall components such as lipopo-
lysaccharide [30]. Another recent study published in Nature has re-
ported that treatment with Lactobacillus murinus prevented salt-sensitive
hypertension by modulating TH17 cells, as the immune system has been
found to be implicated in the development of hypertension, particularly
interleukin-17A (IL-17A)-producing CD4+ TH17 cells. The authors
demonstrated that induction of TH17 cells depends on gut microbiota as
they connected high salt intake to the gut–immune axis and highlighted
that gut microbiome could be a potential therapeutic target to coun-
teract salt-sensitive conditions. They also demonstrated that diet-in-
duced shifts in microbiome composition may have profound effects on
the host, especially on T cells and that TH17 cells are particularly af-
fected by the abundance of specific commensal bacteria, and accord-
ingly daily treatment with L. murinus led to a significant reduction in
systolic blood pressure and normalization of diastolic blood pressure in
animal models, and they corroborated their findings in humans by
conducting an exploratory pilot study in healthy male volunteers.
More studies are needed to further assess the role of Lactobacillus
Plantarum on hypertensive patients especially that this specific
Table 3
: Subgroup analysisa.
subgroup
WMD (95 % CI) Test for overall effect Test for heterogeneity I2(%)
Duration of study, weeks
≤7 weeks
SBP −0.82 [-1.82, 0.18] P = 0.11 P = 0.49 0
DBP −0.49 [-1.20, 0.22] P = 0.17 P = 0.88 0
>7 weeks
SBP −3.65 [-8.12, 0.81] P = 0.11 P = 0.14 49
DBP −0.49 [-1.20, 0.22] P = 0.17 P = 0.88 0
Blood pressure stage, mm Hg
Normal
SBP −0.18 [-4.02, 3.65] P = 0.93 P = 0.58 0
DBP −0.10 [-2.10, 1.90] P = 0.92 P = 0.35 0
Elevated
SBP
DBP
−2.50 [-8.29, 3.29]−
1.80 [-5.67, 2.07]
P = 0.40
P = 0.37
Not applicable
Not applicable
Not applicable
Not applicable
Hypertension SBP
DBP
−1.92 [-3.95, 0.10]−
1.11 [-1.94, -0.27]
P = 0.06
P = 0.010
P = 0.04
P = 0.30
60
19
Supplement compounds Lactobacillus plantarum
Multi-strain probiotic
SBP
DBP
SBP
DBP
−1.81 [-3.59, -0.02]
-1.02 [-1.64, -0.41]
−0.67 [-4.53, 3.19]
P = 0.05
P = 0.001
P = 0.73
P = 0.93
P = 0.07
P = 0.42
P = 0.41
P = 0.31
50
0
0
2
a Abbreviations: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; WMD, weighted mean difference; CI, confidence interval; I2,
percentage score for heterogeneity.
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probiotic has been reported to act by different mechanisms including
reduction of total cholesterol levels, γ-glutamyl transpeptidase, low-
density lipoprotein, glucose, homocysteine and interleukin-6 that has
been reported specifically in postmenopausal women [33]. All this
might add to its benefits regarding the decrease of risk of cardiovascular
disease among vulnerable populations.
4.1. Strengths and limitations
The main strength of this systematic review is our assessing the role
of a specific species of probiotics, which has been recommended, given
the diversity of probiotics and the different mechanisms by which they
can act on the human body. This is specifically relevant when studying
hypertension where a number of pathophysiological mechanisms are
involved, in addition to the fact that the BP-lowering effects of specific
probiotics are still unclear.
We also consider that we have carefully stratified the results by
some relevant variables including the mode of administration of
Lactobacillus and the baseline blood pressure status, which have shown
that the antihypertensive effect of this specific probiotic strain is re-
stricted to those with basal hypertension. The main limitation of our
study is the relatively small number of retrieved studies, though it was
expected given the specificity of the probiotic species chosen to be
studied. Moreover, all sub-strains of Lactobacillus Plantarum were
pooled in the analysis, whereas different sub-strains may exert variable
results which should be considered as a potential limitation. Also,
though meta-analyses have shown significant results, the strength of the
retrieved potential association between Lactobacillus Plantarum admin-
istration and a lower systolic and diastolic blood pressure in hy-
pertensive patients is weak and should be interpreted accordingly.
5. Conclusions
The findings of the present meta-analysis study support the use of
Lactobacillus plantarum supplementation for lowering systolic and dia-
stolic blood pressure. Additionally, unlike normal and elevated blood
pressure subgroups, subjects with hypertension revealed a significant
reduction in diastolic blood pressure. Furthermore, our work elucidated
that single strain supplements of Lactobacillus plantarum may exert
beneficial SBP and DBP-reducing effects in compared with the multi-
strain supplements subgroup. The clinical significance of blood pres-
sure-lowering effect of Lactobacillus Plantarum supplementation is not
considerable; however, given the overarching benefits evident and
concurrent lack of specific side effects, further trials are warranted to
clarify the effects of Lactobacillus Plantarum probiotics particularly for
hypertensive patients.
Fig. 3. Sensitivity analysis for the association between lactobacillus plantarum supplementation and (A) SBP and (B) DBP.
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